(Q50865058)

English

The effect of glucose and glucagon-like peptide-1 stimulation on insulin release in the perfused pancreas in a non-insulin-dependent diabetes mellitus animal model.

scientific article published in September 1998

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/9751230

The effect of glucose and glucagon-like peptide-1 stimulation on insulin release in the perfused pancreas in a non-insulin-dependent diabetes mellitus animal model. (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/9751230

0 references

author name string

Shen HQ

1

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/9751230

Roth MD

2

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/9751230

Peterson RG

3

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/9751230

publication date

1 September 1998

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/9751230

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/9751230

47

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/9751230

9

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/9751230

1042-1047

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/9751230

Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37).

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990275-X

7 January 2021

The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990275-X

7 January 2021

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990275-X

7 January 2021

Glucagon-Like Peptide I Enhances the Insulinotropic Effect of Glibenclamide in NIDDM Patients and in the Perfused Rat Pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990275-X

7 January 2021

The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990275-X

7 January 2021

Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990275-X

7 January 2021

Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990275-X

7 January 2021

Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990275-X

7 January 2021

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990275-X

7 January 2021

Underexpression of beta cell high Km glucose transporters in noninsulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990275-X

7 January 2021

Impaired pulsatile secretion of insulin in relatives of patients with non-insulin-dependent diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990275-X

7 January 2021

Genetically obese rats with (SHR/N-cp) and without diabetes (LA/N-cp) share abnormal islet responses to glucose

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990275-X

7 January 2021

A Rat Pancreas-Small Gut Preparation for the Study of Intestinal Factor(s) and Insulin Release

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990275-X

7 January 2021

Glucagon secretion from the perfused rat pancreas. Studies with glucose and catecholamines

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990275-X

7 January 2021

Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990275-X

7 January 2021

Structure-activity relationships of glucagon-like peptide-1(7-36)amide: insulinotropic activities in perfused rat pancreases, and receptor binding and cyclic AMP production in RINm5F cells

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990275-X

7 January 2021

Comparison of an enzyme-linked immunosorbent assay (ELISA) with a radioimmunoassay (RIA) for the measurement of rat insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990275-X

7 January 2021

Comparison of the effects of glucagon-like peptide-1-(1-37) and -(7-37) and glucagon on islet hormone release from isolated perfused canine and rat pancreases

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990275-X

7 January 2021

Effects of truncated glucagon-like peptide-1 on the responses of starved sheep to glucose

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990275-X

7 January 2021

Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990275-X

7 January 2021

Age and sex variations in glucose tolerance and insulin responses: parallels with cardiovascular risk

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990275-X

7 January 2021

Hyperinsulinemia, sex, and risk of atherosclerotic cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990275-X

7 January 2021

Gut hormones and diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990275-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0026-0495(98)90275-X

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/9751230

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/9751230

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50865058&oldid=1391798372"